9 Jan 2018 07:00
9 January 2018
UDG Healthcare plc
Notice of Q1 2018 Trading Update
UDG Healthcare plc ("UDG Healthcare" or "Group"), a leading international healthcare services provider, will issue a trading update for the first quarter to 31 December 2017 at 7.00 a.m. (GMT) on Tuesday, 30 January 2018.
The Company will also host a conference call for investors and analysts at 9.00am (GMT) on Tuesday, 30 January 2018 to discuss the statement. The dial-in details are as follows:
Standard International Access | +44 (0) 20 3003 2666 |
UK Toll Free | 0808 109 0700 |
Ireland | +353 (0) 1 436 0959 |
Password | UDG |
A playback facility will be available for seven days on +44 (0) 20 8196 1998. The access code for the replay will be 8908246#.
For further information, please contact:
Keith Byrne
Head of Investor Relations, Strategy & Corporate Communications
UDG Healthcare plc
Tel: +353-1-468-9000
Lisa Kavanagh / Jack Hickey / Isabelle Saber
Powerscourt
Tel: +44-207-250-1446
Email: udghealthcare@powerscourt-group.com
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering advisory, commercial, clinical, communications and packaging services to the healthcare industry, employing over 9,000 people with operations in 24 countries and delivering services in over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three broad areas of activity: advisory, communications and commercial & clinical services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.
Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state-of-the-art facilities in the US and Europe.
Aquilant is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.
The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com